Diurnal Group PLC - Cardiff-headquartered pharmaceutical company - Revenue in year ended June 30 multiplies to GBP6.3 million from GBP1.0 million. Pretax loss narrows to GBP5.3 million from GBP14.4 million. "During the financial year we have made significant progress as a business, both financially and operationally. We have increased our commercial footprint in key markets whilst advancing both Alkindi Sprinkle in the US and Chronocort in Europe along their respective regulatory pathways," says Chief Executive Officer Martin Whitaker.
Current stock price: 58.72 pence
Year-to-date change: up more than double from 28.00p
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
